美国食品药品监督管理局批准摘要:艾拉司群用于雌激素受体阳性、人表皮生长因子受体2阴性、ESR1突变的晚期或转移性乳腺癌
美国食品药品监督管理局(FDA)批准艾拉司群用于绝经后女性或成年男性雌激素受体阳性(ER+)、人表皮生长因子受体2阴性(HER2-)、ESR1突变的晚期或转移性乳腺癌,且至少一线内分泌治疗后疾病进展。批准基于EMERALD随机多中心试验,在ESR1突变亚组中无进展生存期(PFS)风险比(HR)为0.55(95%CI 0.39-0.77,P=0.0005),总生存期(OS)无损害趋势(HR 0.90,95%CI 0.63-1.30)。
要点
- 艾拉司群获批限于ER+、HER2-、ESR1突变的晚期或转移性乳腺癌患者。
- ESR1突变亚组PFS HR为0.55(95%CI 0.39-0.77,P=0.0005),OS无损害趋势(HR 0.90,95%CI 0.63-1.30)。
- 无ESR1突变患者获益-风险评估不利;艾拉司群是首个获FDA批准用于ESR1突变患者的口服雌激素受体拮抗剂。
核心结论
- 艾拉司群在ER+、HER2-晚期或转移性乳腺癌中的批准限于ESR1突变患者。
- ESR1突变亚组获益-风险评估有利,基于PFS统计学显著改善且安全性可接受、无OS潜在损害证据。
- 无ESR1突变患者的获益-风险评估不利。
- 艾拉司群是首个获FDA批准用于ESR1突变患者的口服雌激素受体拮抗剂。
研究设计与样本
- 批准基于EMERALD(研究RAD1901-308),一项随机、开放标签、活性对照、多中心试验。
- 共纳入478例ER+、HER2-晚期或转移性乳腺癌患者,其中228例携带有ESR1突变。
- 患者按1:1随机分配接受艾拉司群345 mg口服每日一次(n=239)或研究者选择的内分泌治疗(n=239)。
主要发现
- 在ESR1突变亚组中,盲态独立中心评估的PFS显示统计学显著改善(n=228;HR 0.55,95%CI 0.39-0.77;P=0.0005)。
- ESR1突变亚组中OS终点未达到,但无潜在OS损害趋势(HR 0.90,95%CI 0.63-1.30)。
- 意向治疗(ITT)人群PFS也达到统计学显著(N=478;HR 0.70,95%CI 0.55-0.88;P=0.0018)。
- ITT人群PFS改善主要归因于ESR1突变亚组患者的结果。
- 接受艾拉司群治疗的患者中恶心、呕吐和血脂异常的发生率更高。
关键数值与推荐
- 艾拉司群获批用于绝经后女性或成年男性ER+、HER2-、ESR1突变的晚期或转移性乳腺癌,且至少一线内分泌治疗后疾病进展。
- ESR1突变亚组PFS HR 0.55(95%CI 0.39-0.77;P=0.0005)。
- ESR1突变亚组OS HR 0.90(95%CI 0.63-1.30)。
- ITT人群PFS HR 0.70(95%CI 0.55-0.88;P=0.0018)。
临床怎么用
- 艾拉司群适用于绝经后女性或成年男性ER+、HER2-、ESR1突变的晚期或转移性乳腺癌,且至少一线内分泌治疗后疾病进展。
- 无ESR1突变患者不适用艾拉司群,因其获益-风险评估不利。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The US Food and Drug Administration (FDA) approved elacestrant for the treatment of postmenopausal women or adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression after at least one line of endocrine therapy (ET). PATIENTS AND METHODS: Approval was based on EMERALD (Study RAD1901-308), a randomized, open-label, active-controlled, multicenter trial in 478 patients with ER+, HER2- advanced or metastatic breast cancer, including 228 patients with ESR1 mutations. Patients were randomly assigned (1:1) to receive either elacestrant 345 mg orally once daily (n = 239) or investigator's choice of ET (n = 239). RESULTS: In the ESR1-mut subgroup, EMERALD demonstrated a statistically significant improvement in progression-free survival (PFS) by blinded independent central review assessment (n = 228; hazard ratio [HR], 0.55 [95% CI, 0.39 to 0.77]; P value = .0005). Although the overall survival (OS) end point was not met, there was no trend toward a potential OS detriment (HR, 0.90 [95% CI, 0.63 to 1.30]) in the ESR1-mut subgroup. PFS also reached statistical significance in the intention-to-treat population (ITT, N = 478; HR, 0.70 [95% CI, 0.55 to 0.88]; P value = .0018). However, improvement in PFS in the ITT population was primarily attributed to results from patients in the ESR1-mut subgroup. More patients who received elacestrant experienced nausea, vomiting, and dyslipidemia. CONCLUSION: The approval of elacestrant in ER+, HER2- advanced or metastatic breast cancer was restricted to patients with ESR1 mutations. Benefit-risk assessment in the ESR1-mut subgroup was favorable on the basis of a statistically significant improvement in PFS in the context of an acceptable safety profile including no evidence of a potential detriment in OS. By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable. Elacestrant is the first oral estrogen receptor antagonist to receive FDA approval for patients with ESR1 mutations.
引用
- Shah M, Lingam H, Gao X, et al. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. J Clin Oncol. 2024. PMID: 38381994. doi:10.1200/JCO.23.02112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。